Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 13;40(10):2376–2390. doi: 10.1161/ATVBAHA.120.314284

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors.

Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Effects of single or combined inhibition of mitochondrial respiration and glycolysis by metabolic inhibitors on platelet aggregation. Oxygen consumption rate (OCR; A) and extracellular acidification rate (ECAR; B) measurements of human washed platelets (WP) untreated (CONT) or treated with DMSO (as a vehicle), 2-deoxy-D-glucose (2DG), 3PO (3-[3-pyridinyl]-1-[4-pyridinyl]-2E-propen-1-one), oligomycin (OLIG), antimycin A (AA), rotenone (ROT) or UK-5099, presented as % of basal 20 minutes after addition of the reagents. Data represent the means±SD of 3 independent experiments; n=4–8 replicates in each experiment. C, Aggregation of platelets (WP) untreated (CONT) or treated with 2DG, 3PO, oligomycin, antimycin A, rotenone or UK-5099, and activated with thrombin (0.5 U/mL), presented as % of control; data represent the means±SD of 4 independent experiments, n=1–3 replicates in each experiment. D, OCR and ECAR measurements of WP treated with combined inhibitors: 2DG and oligomycin presented as % of basal 20 min after addition of the reagents. E, Aggregation of WP treated with combined inhibitors: 2DG and oligomycin (10 μg/mL) activated with thrombin (0.5 U/mL); presented as % of control. Data represent the means±SD of 3 independent experiments. F, Intraplatelet ATP concentration in WP treated with combined inhibitors: 2DG and oligomycin, measured in the presence of apyrase (1 U/mL). Data represent the means±SD of 3 independent experiments. *P<0.05, #P<0.01, $P<0.001, &P<0.0001 as compared with control group.